The aim of the study is to determine if the development of thyroid disease during treatment with Ribavirin and Interferon-alpha for chronic hepatitis C delivers a better chance of achieving a viral cure.

Not Applicable

Completed

• Conditions: Inflammatory and Immune System - Other inflammatory or immune system disorders; Chronic hepatitis C; Metabolic and Endocrine - Thyroid disease; Thyroid Disease; Thyroid disease

• Registration Number: ACTRN12610000830099
• Lead Sponsor: Hunter Area Pathology Service

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-10-05
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients with thyroid disease during treatment for chronic hepatitis C vs. no thyroid disease.

Exclusion Criteria

Cirrhosis, pre-existing thyroid diseases, hepatitides other than hepatitis C.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sustained Virologic Response in patients undergoing combination Interferon-alpha and Ribavirin treatments. Sustained virologic response is defined as undetectable Hepatitis C virus-ribonucleic acid (HCV-RNA) by polymerase chain reaction (PCR) tests at 6 months after completion of combination treatment.[Six months after the completion of above treatment.]

Secondary Outcome Measures

Name	Time	Method
/A[N/A]